Cargando…

Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes

BACKGROUND: Sodium-glucose co-transporter 2 inhibitors have been shown to reduce body weight. However, little is known about whether a reduction in body weight affects glycemic and non-glycemic parameters. OBJECTIVES: The aim of this study was to investigate the link between the changes in body weig...

Descripción completa

Detalles Bibliográficos
Autores principales: Kutoh, Eiji, Murayama, Teruma, Wada, Asuka, Hirate, Mitsuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114207/
https://www.ncbi.nlm.nih.gov/pubmed/27798769
http://dx.doi.org/10.1007/s40268-016-0149-5
_version_ 1782468306090852352
author Kutoh, Eiji
Murayama, Teruma
Wada, Asuka
Hirate, Mitsuru
author_facet Kutoh, Eiji
Murayama, Teruma
Wada, Asuka
Hirate, Mitsuru
author_sort Kutoh, Eiji
collection PubMed
description BACKGROUND: Sodium-glucose co-transporter 2 inhibitors have been shown to reduce body weight. However, little is known about whether a reduction in body weight affects glycemic and non-glycemic parameters. OBJECTIVES: The aim of this study was to investigate the link between the changes in body weight and those in metabolic parameters in drug-naïve subjects with type 2 diabetes mellitus (T2DM) receiving ipragliflozin monotherapy. METHODS: Subjects received ipragliflozin monotherapy 25–50 mg/day for 3 months (n = 33). They were then divided into two groups: group L (‘lost’; n = 17) comprised patients who lost weight (change [Δ] in body mass index [BMI] ≤ −0.75, p < 0.00001), and group N (‘neutral’; n = 16) comprised patients who did not lose weight (ΔBMI > −0.75, not significant [NS]). RESULTS: In these two groups, similar reductions were observed in glycated hemoglobin (HbA(1c)) levels (group L: 9.76–8.02%, p < 0.00001; group N: 10.07–8.36%, p < 0.0005). Homeostasis model assessment (HOMA)-B levels increased in both groups, with inter-group differences (p < 0.05; +38.91 vs. +96.83% in group L and N, respectively). However, some parameters showed distinct regulatory patterns. For instance, in group L, reductions were observed in HOMA-R (−20.18%, p < 0.04) and uric acid (UA; −8.91%, p < 0.02) levels. Correlations were seen between the change in HOMA-R and those in fasting blood glucose (FBG) levels (R = 0.557, p < 0.02). Non-significant increases in free fatty acid (FFA) levels and decreases in non-high-density lipoprotein cholesterol (non-HDL-C) or low-density lipoprotein cholesterol (LDL-C) levels were also noted. In group N, reductions in FFA levels (−17.07%, p < 0.05) were observed, and negative correlations were seen between ΔHOMA-B and ΔFBG (R = −0.4781, p < 0.05) and between Δ FFA and Δ HOMA-B levels (R = −0.4305, p < 0.05). Non-significant increases in non-HDL-C and LDL-C levels were also noted. Inter-group differences existed between group L and group N in the changes in non-HDL-C and LDL-C levels (both p < 0.05). CONCLUSIONS: These results indicate that ipragliflozin may possess distinct dual glucose-lowering mechanisms depending on body weight changes. Degrees of insulin resistance decrease in subjects who lose weight. Conversely, ipragliflozin reduces lipotoxicity (FFA levels), thereby activating beta-cell function, in subjects who do not lose weight. Similar glycemic efficacies were observed in both cases. In patients who lost weight, ipragliflozin was associated with improvements in the levels of metabolic parameters related to cardiovascular risk factors, including UA and atherogenic lipid levels (non-HDL-C and LDL-C) compared with those who did not lose weight.
format Online
Article
Text
id pubmed-5114207
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-51142072016-11-29 Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes Kutoh, Eiji Murayama, Teruma Wada, Asuka Hirate, Mitsuru Drugs R D Original Research Article BACKGROUND: Sodium-glucose co-transporter 2 inhibitors have been shown to reduce body weight. However, little is known about whether a reduction in body weight affects glycemic and non-glycemic parameters. OBJECTIVES: The aim of this study was to investigate the link between the changes in body weight and those in metabolic parameters in drug-naïve subjects with type 2 diabetes mellitus (T2DM) receiving ipragliflozin monotherapy. METHODS: Subjects received ipragliflozin monotherapy 25–50 mg/day for 3 months (n = 33). They were then divided into two groups: group L (‘lost’; n = 17) comprised patients who lost weight (change [Δ] in body mass index [BMI] ≤ −0.75, p < 0.00001), and group N (‘neutral’; n = 16) comprised patients who did not lose weight (ΔBMI > −0.75, not significant [NS]). RESULTS: In these two groups, similar reductions were observed in glycated hemoglobin (HbA(1c)) levels (group L: 9.76–8.02%, p < 0.00001; group N: 10.07–8.36%, p < 0.0005). Homeostasis model assessment (HOMA)-B levels increased in both groups, with inter-group differences (p < 0.05; +38.91 vs. +96.83% in group L and N, respectively). However, some parameters showed distinct regulatory patterns. For instance, in group L, reductions were observed in HOMA-R (−20.18%, p < 0.04) and uric acid (UA; −8.91%, p < 0.02) levels. Correlations were seen between the change in HOMA-R and those in fasting blood glucose (FBG) levels (R = 0.557, p < 0.02). Non-significant increases in free fatty acid (FFA) levels and decreases in non-high-density lipoprotein cholesterol (non-HDL-C) or low-density lipoprotein cholesterol (LDL-C) levels were also noted. In group N, reductions in FFA levels (−17.07%, p < 0.05) were observed, and negative correlations were seen between ΔHOMA-B and ΔFBG (R = −0.4781, p < 0.05) and between Δ FFA and Δ HOMA-B levels (R = −0.4305, p < 0.05). Non-significant increases in non-HDL-C and LDL-C levels were also noted. Inter-group differences existed between group L and group N in the changes in non-HDL-C and LDL-C levels (both p < 0.05). CONCLUSIONS: These results indicate that ipragliflozin may possess distinct dual glucose-lowering mechanisms depending on body weight changes. Degrees of insulin resistance decrease in subjects who lose weight. Conversely, ipragliflozin reduces lipotoxicity (FFA levels), thereby activating beta-cell function, in subjects who do not lose weight. Similar glycemic efficacies were observed in both cases. In patients who lost weight, ipragliflozin was associated with improvements in the levels of metabolic parameters related to cardiovascular risk factors, including UA and atherogenic lipid levels (non-HDL-C and LDL-C) compared with those who did not lose weight. Springer International Publishing 2016-10-31 2016-12 /pmc/articles/PMC5114207/ /pubmed/27798769 http://dx.doi.org/10.1007/s40268-016-0149-5 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Kutoh, Eiji
Murayama, Teruma
Wada, Asuka
Hirate, Mitsuru
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
title Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
title_full Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
title_fullStr Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
title_full_unstemmed Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
title_short Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
title_sort distinct glucose-lowering mechanisms of ipragliflozin depending on body weight changes
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114207/
https://www.ncbi.nlm.nih.gov/pubmed/27798769
http://dx.doi.org/10.1007/s40268-016-0149-5
work_keys_str_mv AT kutoheiji distinctglucoseloweringmechanismsofipragliflozindependingonbodyweightchanges
AT murayamateruma distinctglucoseloweringmechanismsofipragliflozindependingonbodyweightchanges
AT wadaasuka distinctglucoseloweringmechanismsofipragliflozindependingonbodyweightchanges
AT hiratemitsuru distinctglucoseloweringmechanismsofipragliflozindependingonbodyweightchanges